Structure Therapeutics (NASDAQ:GPCR) Hits New 52-Week Low – Here’s Why

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)’s stock price reached a new 52-week low on Wednesday. The stock traded as low as $20.50 and last traded at $20.7660, with a volume of 174,301 shares changing hands. The stock had previously closed at $21.55.

Analyst Ratings Changes

A number of equities research analysts have weighed in on GPCR shares. Weiss Ratings downgraded Structure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. HC Wainwright reiterated a “buy” rating on shares of Structure Therapeutics in a report on Wednesday, September 9th. Wall Street Zen lowered Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 3rd. Canaccord Genuity Group set a $111.00 price target on shares of Structure Therapeutics in a research report on Friday, August 7th. Finally, Citizens Jmp reiterated a “market outperform” rating and set a $110.00 price target on shares of Structure Therapeutics in a research report on Wednesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.91.

Structure Therapeutics Price Performance

The company has a market cap of $1.48 billion, a P/E ratio of -21.20 and a beta of -1.30. The company’s 50-day moving average is $35.29 and its two-hundred day moving average is $50.14.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Equities research analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.87 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Sterling Capital Management LLC bought a new position in Structure Therapeutics during the 1st quarter valued at about $28,000. IFP Advisors Inc bought a new stake in shares of Structure Therapeutics during the 2nd quarter worth approximately $46,000. Assetmark Inc. grew its position in Structure Therapeutics by 21.4% in the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after acquiring an additional 449 shares during the last quarter. Janney Montgomery Scott LLC purchased a new stake in Structure Therapeutics in the first quarter worth $329,000. Finally, Cetera Investment Advisers lifted its position in shares of Structure Therapeutics by 17.0% during the first quarter. Cetera Investment Advisers now owns 7,720 shares of the company’s stock worth $372,000 after purchasing an additional 1,124 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic diseases. The company uses structure-based drug discovery and focuses on G protein-coupled receptors (GPCRs), a broad class of drug targets involved in metabolic and cardiovascular processes.

Its lead product candidate is GSBR-1290, an investigational oral GLP-1 receptor agonist being developed for obesity and type 2 diabetes. Structure Therapeutics is also advancing additional discovery and preclinical programs intended to address metabolic and related chronic diseases.